Seung Suh Hong
Director/Miembro de la Junta en OCULAR THERAPEUTIX, INC. .
Fortuna: 50 918 $ al 31/05/2024
Perfil
Seung Suh Hong's current job(s) include Vice Chairman at Novalgen Ltd., Vice Chairman at Novelgen Co. Ltd(South Korea), Independent Director at Ocular Therapeutix, Inc., and President & Chief Operating Officer at Cellemedy Co., Ltd.
.
Dr. Hong's former job(s) include President & Chief Executive Officer at Celltrion Healthcare Co., Ltd.
from 2002 to 2015, and President at Celltrion Healthcare Japan KK from 2016 to 2019.
Dr. Hong's education history includes undergraduate, graduate, and doctorate degrees from Seoul National University.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
OCULAR THERAPEUTIX INC
0.01% | 31/03/2024 | 8 933 ( 0.01% ) | 50 918 $ | 31/05/2024 |
Cargos activos de Seung Suh Hong
| Empresas | Cargo | Inicio |
|---|---|---|
| OCULAR THERAPEUTIX, INC. | Director/Miembro de la Junta | 11/06/2019 |
Cellemedy Co., Ltd.
 Cellemedy Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Cellemedy Co., Ltd. develops next-generation cancer treatments to improve the health of people suffering from cancer. The company is based in Seongnam-si, South Korea. The South Korean company was founded in 2016. The CEO is Ha-Chul Kim. | Presidente | 01/01/2021 |
Novalgen Ltd.
 Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | Director/Miembro de la Junta | 01/01/2021 |
| Novelgen Co. Ltd(South Korea) | Director/Miembro de la Junta | 01/04/2020 |
Antiguos cargos conocidos de Seung Suh Hong.
| Empresas | Cargo | Fin |
|---|---|---|
| Celltrion Healthcare Japan KK | Presidente | 02/01/2019 |
| CELLTRION HEALTHCARE CO., LTD. | Director Ejecutivo | 01/12/2015 |
Formación de Seung Suh Hong.
| Seoul National University | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| OCULAR THERAPEUTIX, INC. | Health Technology |
| Empresas privadas | 5 |
|---|---|
Celltrion Healthcare Co., Ltd.
 Celltrion Healthcare Co., Ltd. Pharmaceuticals: MajorHealth Technology Celltrion Healthcare Co., Ltd. manufactures pharmaceutical products. Its products include infliximab, rituximab, and trastuzumab biosimilars. The company was founded on December 29, 1999 and is headquartered in Incheon, South Korea. | Health Technology |
| Celltrion Healthcare Japan KK | |
Novalgen Ltd.
Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | Health Technology |
Cellemedy Co., Ltd.
Cellemedy Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Cellemedy Co., Ltd. develops next-generation cancer treatments to improve the health of people suffering from cancer. The company is based in Seongnam-si, South Korea. The South Korean company was founded in 2016. The CEO is Ha-Chul Kim. | Commercial Services |
| Novelgen Co. Ltd(South Korea) |
- Bolsa de valores
- Insiders
- Seung Suh Hong
